ChromaDex
CDXC

$3.07

3.76%

Market Cap: 232M

Healthcare Medicinal Chemicals & Botanical Products

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 5 analysts

0

News positive %

of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

176% more capital invested

Capital invested by funds: $16.5M [Q4 2023] → $45.7M (+$29.1M) [Q1 2024]

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

98% more call options, than puts

Call options by funds: $513K | Put options by funds: $259K

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

26% more funds holding

Funds holding: 53 [Q4 2023] → 67 (+14) [Q1 2024]

2.04% more ownership

Funds ownership: 15.4% [Q4 2023] → 17.43% (+2.04%) [Q1 2024]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

95%

upside

Avg. target

$6

95%

upside

High target

$6

95%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Raghuram Selvaraju	95%upside $6	Buy Reiterated	15 Jul 2024
Roth MKM Sean McGowan	95%upside $6	Buy Maintained	12 Jun 2024
HC Wainwright & Co. Raghuram Selvaraju	95%upside $6	Buy Reiterated	9 May 2024
Roth MKM Sean McGowan	95%upside $6	Buy Maintained	9 Apr 2024
HC Wainwright & Co. Raghuram Selvaraju	95%upside $6	Buy Maintained	11 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CDXC published over the past 30 days

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced that it will hold a conference call on Wednesday, August 7, 2024 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Invest.

ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company's healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boos.

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces the appointment of Carlos Lopez as Senior Vice President, General Counsel. Mr. Lopez will oversee the organization's legal function, including corporate governance, securities, intellectual property, and litigation. Effective today, July 22, 2024, he will report directly to Rob Fried, CEO of ChromaDex and Founder of Tru N.

ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announces Wells Pharma of Houston will begin shipping limited quantities of pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC), branded Niagen+, to select IV clinics including Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore.

ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August

ChromaDex to Join Russell 2000® Index

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced its inclusion in the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes. This inclusion will be effective at the opening of U.S. equity markets on Monday, July 1, 2024, based on the preliminary list of additions posted on Friday, May 24, 2024. Rob Fried, CEO of ChromaDex and Founde.

ChromaDex to Join Russell 2000® Index

ChromaDex: Looking To Take The Big Step Into Pharma

ChromaDex Corporation is a leader in NAD+ development for healthy aging with Tru Niagen, showing strong growth and attractive valuation. ChromaDex is making a move into the pharma industry with NRC candidate for AT, receiving FDA designations and preparing for clinical trials. Potential risks include cash burn, competition, and IP challenges, but the company's dual focus on pharma and nutraceuticals offers significant upside.

ChromaDex: Looking To Take The Big Step Into Pharma

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II clinical study showcasing the promising effects of nicotinamide riboside (NR) supplementation for people with peripheral artery disease (PAD). This study was part of the ChromaDex External Research Program (CERP®), which donated ChromaDex's patented NR ingredient, Niagen®, the most efficient and high-quality NAD+ precurs.

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen® (patented nicotinamide riboside chloride or NRC). Authorized by the U.S. FDA for compounding by 503B outsourcing facilities, pharmaceutical-grade intravenous (IV) and injectable NRC will be available in IV, shot, and push forms exclusively at clinics, with a.

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

Zacks Investment Research

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that the U.S. Food & Drug Administration (FDA) granted Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for NRC, the company's product candidate for the treatment of Ataxia Telangiectasia (AT). Plans are underway to file an Investigational New Drug (IND) application with the U.S. FDA in anticipatio.

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

See News Rankings